News & Insights
Sort By
Insights 331 Results
Insights
|October 23, 2026
Gunderson Dettmer partner Melissa Marks spoke with WSJ Pro Venture Capital about pro rata rights in venture capital investments and how they shape negotiations over investor allocations in follow-on financing rounds.
Insights
|October 21, 2026
Client Insight: Quarterly Employment Law Update – Fall 2026
This update highlights employment-law developments affecting innovation-economy employers, including new AI and monitoring requirements, restrictions on repayment agreements, and expanded leave and pay-transparency obligations. Employers should prioritize requirements taking effect this fall while preparing policies, templates, and payroll systems for 2027.
Insights
|October 20, 2026
Gunderson Dettmer partner John Yates spoke with Capital Analytics Associates about Atlanta’s opportunities in applied artificial intelligence, the funding environment for local startups, and ongoing initiatives to attract investors to the region.
Events 117 Results
Events
|October 15, 2026
Webinar: Taking a Company Public: Lessons from IPO-Tested GCs
Approaching your IPO prep with clarity and perspective will lay the groundwork for a smooth transition to operating as a public company.
Events
|June 9, 2026
In this third installment of the series, Tim Ehrlich, chair of Gunderson Dettmer’s Life Sciences Group, interviewed Jefferies vice chairman of Global Healthcare Investment Banking Phil Ross
Events
|March 31, 2026
This session gives CFOs and GCs of late-stage private companies a practical, end-to-end IPO roadmap—from drafting the S-1 and structuring the offering to investor meetings, pricing, lockups, and the 2026 market outlook
Client News 1,656 Results
Client News
|October 27, 2026
Infisical Raises $40 Million Series B at $600 Million Valuation
Infisical announces its $40 million Series B financing at a $600 million valuation.
Client News
|October 21, 2026
Gunderson Dettmer represented Jefferies, Leerink Partners, and TD Cowen as representatives of the underwriters in the common stock offering of Arcus Biosciences (NYSE:RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases.
Client News
|October 19, 2026
Town Raises $108 Million Series B at a $1 Billion Valuation
Town announces its $108 million Series B financing, valuing the company at $1 billion.
Firm News 287 Results
Firm News
|October 23, 2026
Gunderson Dettmer Named a Top 10 Investor Counsel in The Deal’s Q3 2026 PIPEs League Tables
Gunderson Dettmer ranked sixth for Investor Legal Counsel in The Deal’s PIPEs League Tables Q3 2026, recognizing the firm’s work advising investors on private investments in public equity (PIPEs).
Firm News
|October 16, 2026
Lawdragon Recognizes Nineteen Gunderson Dettmer Attorneys as Leading Dealmakers in America
Lawdragon recognized eighteen Gunderson Dettmer partners and Chairman Emeritus Robert Gunderson Jr. in the 2027 edition of The 500 Leading Dealmakers in America, an annual list that celebrates transactional excellence, honoring the attorneys without whom no significant deal gets done.
Firm News
|September 25, 2026
Gunderson Dettmer Launches Inaugural Client Development Accelerator
Gunderson Dettmer launched its first client development accelerator, a multi-day workshop connecting early-career partners with firm leaders.
Blog Posts 68 Results
Public Ventures
|October 5, 2026
SEC Staff Grants Broad Relief for Board-Aligned Retail Shareholder Voting Programs
“By giving retail investors access to a no-fee, client-directed process similar to those currently available to institutional investors, [issuer voluntary retail voting programs] will remove time and other burdens borne by retail investors in the voting process, enabling greater participation in shareholder democracy by ultimate asset owners.”
Public Ventures
|September 16, 2026
Glass Lewis Invites Comment on Proposed ‘Four Perspectives’ Proxy Voting Research Model
Beginning in September 2027, Glass Lewis plans to replace its single benchmark voting policy with four distinct proxy voting perspectives reflecting different investor philosophies and stewardship priorities. Its Benchmark Voting Policy Guidelines and Proxy Paper research reports will remain available for the 2027 proxy season, with updated guidelines to be published early next month
Public Ventures
|September 8, 2026
SEC Files Subpoena Enforcement Action Against ISS
“It is wholly appropriate for the SEC to look into whether ISS’s investment advice to clients on proxy voting is driven by a particular political or policy aim to the detriment of its clients’ interests. If it is, then ISS is breaching its fiduciary duties and violating the law.”